^
    Back
    Association details:
    Biomarker:EGFR S768_D770dupSVD
    Cancer:Lung Adenocarcinoma
    Drug:Ivesa (furmonertinib) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Medicine (Baltimore)
    Title:

    First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review

    Published date:
    12/29/2023
    Excerpt:
    The first case included a 38-year-old female who had an EGFR ex20ins mutation (p.S768_D770dupSVD). After 1 month of treatment with furmonertinib, her symptoms of pain and cough were significantly alleviated. She achieved a partial response according to response evaluation criteria in solid tumors. The final progression-free survival was 8.13 months.
    DOI:
    10.1097/MD.0000000000036667